Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6946445

Title:Therapeutic chemokine receptor antagonists
Inventors:Clark-Lewis, Ian; Vancouver, Canada
Gong, Jiang-Hong; Vancouver, Canada
Duronio, Vincent; Delta, Canada
Clark-Lewis, Ian; Vancouver, Canada
Gong, Jiang-Hong; Vancouver, Canada
Duronio, Vincent; Delta, Canada
Summary:This invention provides a variety of therapeutic uses for CXCR4 antagonists, which are typically used for reducing interferon gamma production by T-cells in the treatment of cancer and of autoimmune diseases such as multiple sclerosis, and for the inhibition of angiogenesis. This invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation and with an excipient or carrier, the exact nature of which is disclosed. The CXCR4 antagonists for use in this invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.
Abstract:The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments. CXCR4 antagonsits may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6946445
Application Number:US1999000646192
Date Filed:12/02/1999
Date Published:20/09/2005
Assignee:The University of British Columbia, Vancouver, Canada


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021